Diligence memo · auto-generated · as of July 2, 2026
AJNA BioSciences PBC
AJNA BioSciences PBC looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
AJNA BioSciences PBC operates in Pharmaceuticals, based in LITTLETON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
AJNA BioSciences PBC has raised $9.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.9M on 2021-09-30.
Most recent recorded round closed around 2024-05-28.
Valuation (modeled)modeled
Provath models AJNA BioSciences PBC at approximately $11M (range $2.4M–$25M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.35× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 32 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 3.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 52% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 19% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.